Swissmedic Approval: BeiGene’s BRUKINSA to Treat WM

Swissmedic Approval: BeiGene’s BRUKINSA to Treat WM

BeiGene has announced their Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA (zanubrutinib) has been approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia (WM). WM is a rare B-cell lymphoma that is primarily found in bone marrow and...
Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Canada Approves BeiGene BRUKINSA for Mantle Cell Lymphoma

Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment...